Literature DB >> 16177542

The kallikrein-kinin system: current and future pharmacological targets.

Marie Eve Moreau1, Nancy Garbacki, Giuseppe Molinaro, Nancy J Brown, François Marceau, Albert Adam.   

Abstract

The kallikrein-kinin system is an endogenous metabolic cascade, triggering of which results in the release of vasoactive kinins (bradykinin-related peptides). This complex system includes the precursors of kinins known as kininogens and mainly tissue and plasma kallikreins. The pharmacologically active kinins, which are often considered as either proinflammatory or cardioprotective, are implicated in many physiological and pathological processes. The interest of the various components of this multi-protein system is explained in part by the multiplicity of its pharmacological activities, mediated not only by kinins and their receptors, but also by their precursors and their activators and the metallopeptidases and the antiproteases that limit their activities. The regulation of this system by serpins and the wide distribution of the different constituents add to the complexity of this system, as well as its multiple relationships with other important metabolic pathways such as the renin-angiotensin, coagulation, or complement pathways. The purpose of this review is to summarize the main properties of this kallikrein-kinin system and to address the multiple pharmacological interventions that modulate the functions of this system, restraining its proinflammatory effects or potentiating its cardiovascular properties.

Mesh:

Substances:

Year:  2005        PMID: 16177542     DOI: 10.1254/jphs.srj05001x

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  106 in total

1.  Some new insights into the molecular mechanisms of pain perception.

Authors:  David A Brown; Gayle M Passmore
Journal:  J Clin Invest       Date:  2010-04-26       Impact factor: 14.808

2.  Taking the sting out of pain.

Authors:  I Nagy; C Paule; J White; L Urban
Journal:  Br J Pharmacol       Date:  2007-05-29       Impact factor: 8.739

Review 3.  New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family.

Authors:  Nashmil Emami; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2007-09-15       Impact factor: 6.603

Review 4.  Mode of action of cytokines on nociceptive neurons.

Authors:  Nurcan Uçeyler; Maria Schäfers; Claudia Sommer
Journal:  Exp Brain Res       Date:  2009-03-17       Impact factor: 1.972

5.  C-reactive protein levels in hereditary angioedema.

Authors:  Z L M Hofman; A Relan; C E Hack
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

6.  Effect of two active compounds obtained from the essential oil of Cordia verbenacea on the acute inflammatory responses elicited by LPS in the rat paw.

Authors:  R Medeiros; G F Passos; C E Vitor; J Koepp; T L Mazzuco; L F Pianowski; M M Campos; J B Calixto
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

Review 7.  A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme.

Authors:  Kenneth E Bernstein; Frank S Ong; Wendell-Lamar B Blackwell; Kandarp H Shah; Jorge F Giani; Romer A Gonzalez-Villalobos; Xiao Z Shen; Sebastien Fuchs; Rhian M Touyz
Journal:  Pharmacol Rev       Date:  2012-12-20       Impact factor: 25.468

8.  Estrogen-related receptor γ (ERRγ) regulates oxygen-dependent expression of voltage-gated potassium (K+) channels and tissue kallikrein during human trophoblast differentiation.

Authors:  Yanmin Luo; Premlata Kumar; Carole R Mendelson
Journal:  Mol Endocrinol       Date:  2013-04-12

9.  Blockade of endogenous tissue kallikrein aggravates renal injury by enhancing oxidative stress and inhibiting matrix degradation.

Authors:  Yuying Liu; Grant Bledsoe; Makato Hagiwara; Zhi-Rong Yang; Bo Shen; Lee Chao; Julie Chao
Journal:  Am J Physiol Renal Physiol       Date:  2010-01-20

Review 10.  Heterotrimeric G protein signaling in polycystic kidney disease.

Authors:  Taketsugu Hama; Frank Park
Journal:  Physiol Genomics       Date:  2016-05-13       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.